06-Benzylguanine enhances the sensitivity of a glioma xenograft with low 06-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU
1996

Enhancing Glioma Treatment with 06-Benzylguanine

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): SR Wedge, ES Newlands

Primary Institution: Charing Cross Hospital

Hypothesis

Does 06-benzylguanine enhance the sensitivity of glioma xenografts to temozolomide and BCNU?

Conclusion

06-benzylguanine significantly enhances the anti-tumour activity of temozolomide and BCNU in glioma xenografts.

Supporting Evidence

  • 06-benzylguanine did not inhibit tumour growth when administered alone.
  • Temozolomide and BCNU produced significant tumour growth delays when combined with 06-benzylguanine.
  • AGT activity was significantly reduced after administration of 06-benzylguanine.

Takeaway

Researchers found that a drug called 06-benzylguanine can help make another cancer drug work better against brain tumors in mice.

Methodology

The study evaluated the effect of 06-benzylguanine on the anti-tumour activity of temozolomide and BCNU in athymic mice with human glioma xenografts.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Athymic MF-1 (nu/nu genotype) mice were used in the study.

Statistical Information

P-Value

p<0.002

Statistical Significance

p<0.002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication